Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 2:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 1,659 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Schizophrenia; Psychosis Clear all
Completed Phase 2 Interventional

Huperzine for Cognitive and Functional Impairment in Schizophrenia

NCT00963846
View directory record Official record
Conditions
Schizophrenia
Interventions
placebo, huperzine 0.2 mg BID, huperzine 0.4 mg BID, huperzine 0.8 mg BID
Drug
Lead sponsor
Biomedisyn Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 1, 2013 · Synced Oct 15, 2026, 2:16 PM EDT
Completed Phase 2 Interventional Results available

RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder

NCT01490086
View directory record Official record
Conditions
Acute Schizophrenia, Schizoaffective Disorder
Interventions
RP5063, placebo, aripiprazole
Drug
Lead sponsor
Reviva Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 15, 2026, 2:16 PM EDT
Completed Not applicable Interventional

Evaluating a Collaborative Care Model for the Treatment of Schizophrenia (EQUIP)

NCT00119574
View directory record Official record
Conditions
Schizophrenia Disorders, Chronic Illness, Schizoaffective Disorder, Weight Gain
Interventions
Collaborative Chronic Illness Model
Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 15, 2026, 2:16 PM EDT
Completed No phase listed Observational Results available

Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study

NCT01269710
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder, Not Otherwise Specified, Prodromal Schizophrenia, Mood Disorder, Bipolar Disorder, Major Depressive Disorder, Depressive Disorder, Not Otherwise Specified, Mood Disorder, Not Otherwise Specified, Autism Spectrum Disorder
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
3 Years to 19 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 22, 2013 · Synced Oct 15, 2026, 2:16 PM EDT
Completed Not applicable Interventional

Evaluation of A Statewide Program to Prevent Early Mortality and to Promote Fitness in Persons With SMI

NCT02334280
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Schizoaffective Disorder
Interventions
In SHAPE
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
21 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
4
States / cities
Lebanon, New Hampshire • Manchester, New Hampshire • Nashua, New Hampshire + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Oct 15, 2026, 2:16 PM EDT
Completed Not applicable Interventional

Proactive Psychiatry Consultation for Patients With Cancer and Severe Mental Illness

NCT02594696
View directory record Official record
Conditions
Major Depression, Schizophrenia, Bipolar Disorder, Lung Cancer, Breast Cancer, Head and Neck Cancer, GI Cancer, Cancer
Interventions
Proactive Psychiatry Consultation (PPC)
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 15, 2026, 2:16 PM EDT
Recruiting Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia

NCT07680946
View directory record Official record
Conditions
Schizophrenia
Interventions
Ublituximab
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Little Rock, Arkansas • Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 15, 2026, 2:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Point-of-Care Testing (POCT) Detection and Management of Metabolic Syndrome in Patients With Mental Illness

NCT02029989
View directory record Official record
Conditions
Hyperlipidemia, Diabetes, Hypertension
Interventions
Glucose and lipids, Glycosylated Hemoglobin A1c, Blood Pressure and Heart Rate, Body mass index, Waist and Hip circumference, Comprehensive Medication Management
Device · Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 64 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 15, 2026, 2:16 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Imaging Dopamine D2 Agonist Binding Sites in Schizophrenia

NCT03999190
View directory record Official record
Conditions
Schizophrenia
Interventions
NPA radiotracer, Raclopride radiotracer, Dextroamphetamine
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 35 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 29, 2020 · Synced Oct 15, 2026, 2:16 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia

NCT01009060
View directory record Official record
Conditions
Schizophrenia
Interventions
GSK239512, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
15
States / cities
Garden Grove, California • Los Angeles, California • National City, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 15, 2026, 2:16 PM EDT
Completed Phase 2 Interventional Results available

Study to Demonstrate Cognitive Enhancing Effects of BF2.649

NCT00690274
View directory record Official record
Conditions
Schizophrenia
Interventions
BF2.649, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 15, 2026, 2:16 PM EDT
Withdrawn No phase listed Observational

Exercise Target Brain Oscillations in Psychosis

NCT05338424
View directory record Official record
Conditions
Psychosis, Schizophrenia, Schizoaffective Disorder
Interventions
Sprint Interval Training (SIT)
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 10, 2022 · Synced Oct 15, 2026, 2:16 PM EDT
Completed Phase 2Phase 3 Interventional

High Dose of Quetiapine in Treating Subjects With Treatment Refractory Schizophrenia or Schizoaffective Disorder

NCT00297947
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
quetiapine
Drug
Lead sponsor
Manhattan Psychiatric Center
Other
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
2
States / cities
New York, New York • Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2015 · Synced Oct 15, 2026, 2:16 PM EDT
Completed Phase 1 Interventional Results available

Developing Clinical Tools to Communicate Genetic Risk for Individuals Who Are Clinical High Risk for Psychosis

NCT04325568
View directory record Official record
Conditions
Psychosis
Interventions
PsyGist and Clinician Manual
Behavioral
Lead sponsor
New York University
Other
Eligibility
16 Years to 30 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Oct 15, 2026, 2:16 PM EDT
Completed Not applicable Interventional

An Open-Label Pilot Trial of Alpha Lipoic Acid (ALA) for Weight Loss in Schizophrenia

NCT01355952
View directory record Official record
Conditions
Obesity, Weight Loss, Schizophrenia
Interventions
Alpha Lipoic Acid
Dietary Supplement
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced Oct 15, 2026, 2:16 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder

NCT04030143
View directory record Official record
Conditions
Schizophrenia, Bipolar I Disorder
Interventions
Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
19
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Bellflower, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 15, 2026, 2:16 PM EDT
Completed No phase listed Observational

Cross-Sectional Iloperidone IVGTT

NCT01686815
View directory record Official record
Conditions
Schizophrenia, Serious Mental Illness, Metabolic Syndrome, Insulin Resistance, Glucose Metabolism
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Oct 15, 2026, 2:16 PM EDT
Completed Phase 1 Interventional

Enhancing Motivation To Quit Smoking In Smokers With Serious Mental Illness

NCT00500695
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Motivational Interviewing, Psychoeducation
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Oct 15, 2026, 2:16 PM EDT
Completed Phase 2 Interventional Results available

Effects of Oxytocin Nasal Spray on Social Affiliation

NCT00663039
View directory record Official record
Conditions
Schizophrenia
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 64 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Oct 15, 2026, 2:16 PM EDT
Completed Not applicable Interventional Results available

Specialized Treatment Early in Psychosis (STEP)

NCT00309452
View directory record Official record
Conditions
Schizophrenia and Disorders With Psychotic Features
Interventions
Cognitive Behavioral Group Therapy, Cognitive remediation, Medications, MFG, Assertive case management, Treatment as Usual in the community
Behavioral · Drug · Other
Lead sponsor
Yale University
Other
Eligibility
16 Years to 45 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Oct 15, 2026, 2:16 PM EDT
Recruiting Phase 1Phase 2 Interventional

Cromoglicate Adjunctive Therapy for Outpatients With Schizophrenia

NCT03794076
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder
Interventions
Cromoglycate, Placebo
Drug
Lead sponsor
Vishwajit Nimgaonkar, MD PhD
Other
Eligibility
18 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 15, 2026, 2:16 PM EDT
Completed Phase 4 Interventional Results available

Treating Acutely Agitated Patients With Asenapine Sublingual Tablets

NCT01400113
View directory record Official record
Conditions
Agitation
Interventions
Asenapine, Placebo
Drug
Lead sponsor
Unity Health Toronto
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Oct 15, 2026, 2:16 PM EDT
Completed Phase 1 Interventional

N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia

NCT01885338
View directory record Official record
Conditions
Schizophrenia
Interventions
N-acetylcysteine (NAC), Inactive placebo capsule
Drug
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2015 · Synced Oct 15, 2026, 2:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Cannabis and Schizophrenia: Self-Medication and Agonist Treatment

NCT00946348
View directory record Official record
Conditions
Schizophrenia, Dual Diagnosis, Schizoaffective Disorder, Psychotic Disorder, Cannabis Use Disorder
Interventions
Dronabinol, Cannabis
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Oct 15, 2026, 2:16 PM EDT